Contract 36E79721A0023
Regeneron Pharmaceuticals Inc · Department Of Veterans Affairs · September 29, 2021
Regeneron Pharmaceuticals Inc was awarded a federal contract by Department Of Veterans Affairs on September 29, 2021 for an undisclosed amount of work in pharmaceutical preparation manufacturing. This is a task or delivery order issued under parent IDIQ 36F79721D0169. The contract has been modified 3 times since the base award It uses firm fixed-price contract pricing. The most recent modification was on November 13, 2025. If all options are exercised, the contract could reach $780,000.
Contract details
- PIID
- 36E79721A0023
- Parent IDIQ
- 36F79721D0169
- Award type
- —
- Pricing
- Firm Fixed Price
- Competition
- Full And Open Competition
- NAICS
- 325412 · Pharmaceutical Preparation Manufacturing
- Product / service
- Drugs And Biologicals
- First action
- September 29, 2021
- Latest action
- November 13, 2025
Description
2026 PUBLIC LAW PRICING UPDATES.
Modification timeline
-
November 13, 2025Mod P00009 · Supplemental Agreement For Work Within Scope$0
-
September 8, 2025Mod P00008 · Exercise An OptionEXERCISE OPTION YEAR 4$0
-
August 29, 2024Mod P00006 · Exercise An OptionEXERCISE OPTION YEAR 3$0
-
September 29, 2021Base awardBPA FOR EVKEEZA.$0
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Petnet Solutions, Inc. | Department Of Veterans Affairs | April 1, 2026 | $387.4K |
| Eli Lilly And Company | Department Of Veterans Affairs | April 1, 2026 | $0 |
| Exelan Pharmaceuticals Inc | Department Of Veterans Affairs | April 1, 2026 | $0 |
| Cardinal Health 414, Llc | Department Of Veterans Affairs | April 1, 2026 | $122.9K |
| Guardian Pharmacy Of Indianapolis Nuclear, Llc | Department Of Veterans Affairs | April 1, 2026 | $0 |
| Jubilant Draximage Inc | Department Of Veterans Affairs | April 1, 2026 | $0 |
Top contractors in NAICS 325412
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | Mckesson Corporation | 1,187 | $4.96B |
| 2 | Merck Sharp & Dohme Llc | 26 | $894.71M |
| 3 | Sanofi Vaccines Us Inc. | 57 | $702.38M |
| 4 | Pfizer Inc | 169 | $541.15M |
| 5 | Glaxosmithkline, Llc | 14 | $505.04M |
| 6 | Phlow Corp. | 1 | $105.27M |
| 7 | Exelan Pharmaceuticals Inc | 76 | $104.30M |
| 8 | Seqirus USA Inc | 47 | $59.15M |
| 9 | Emergent Biosolutions Canada Inc | 2 | $53.73M |
| 10 | Mckesson Specialty Distribution Llc | 1 | $51.05M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 36E79721A0023?
Contract 36E79721A0023 is a federal contract awarded to Regeneron Pharmaceuticals Inc by Department Of Veterans Affairs on September 29, 2021 for an undisclosed amount of work classified under PHARMACEUTICAL PREPARATION MANUFACTURING. It has been modified 3 times since the base award.
Who won contract 36E79721A0023?
Regeneron Pharmaceuticals Inc won contract 36E79721A0023 from Department Of Veterans Affairs.
How much is contract 36E79721A0023 worth?
Contract 36E79721A0023 has obligated $0 to date but carries a potential ceiling of $780,000 if fully funded and all options are exercised.